Skip to main content

Advertisement

SpringerLink
Log in

Intranasal immunization with an epitope-based vaccine results in earlier protection, but not better protective efficacy, against Helicobacter pylori compared to subcutaneous immunization

  • Published:
Immunologic Research Aims and scope Submit manuscript

Abstract

The route of vaccination plays an important role in the generation of protective immunity against pathogens. In one of our previous studies, subcutaneous (SC) immunization with Epivac had been shown to induce a local and systemic Th1-biased response but failed to provide complete protection. In this study, we investigated whether intranasal (IN) immunization with Epivac could protect against Helicobacter pylori infection to a greater extent than SC immunization. Despite the generation of high serum IgG levels via the two routes of vaccination, the protective effect was independent of the humoral response level. At 2-week post-challenge, examination of the IgG subclass response showed that a dominant IgG2a response was generated after IN immunization, which coincided with elevated IFN-γ production in both splenocytes and stomach homogenates, and a significant reduction in the H. pylori load was found. In contrast, a balanced Th1/Th2 response was induced by SC immunization at the same time point and no protective effect was observed. Two weeks later, the immune response in the SC vaccination groups shifted to Th1 and was equivalent in protection to the IN vaccination route. Our results showed that IN vaccination elicited earlier systemic and gastric Th1 response, which may contribute to the earlier protection compared to SC vaccination.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Wotherspoon AC, Doglioni C, Diss TC, Pan L, Moschini A, de Boni M, et al. Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet. 1993;342(8871):575–7.

    Article  CAS  PubMed  Google Scholar 

  2. NIH Consensus Conference. Helicobacter pylori in peptic ulcer disease. NIH Consensus Development Panel on Helicobacter pylori in peptic ulcer disease. JAMA. 1994;272(1):65–9.

    Article  Google Scholar 

  3. Covacci A, Telford JL, Del Giudice G, Parsonnet J, Rappuoli R. Helicobacter pylori virulence and genetic geography. Science. 1999;284(5418):1328–33.

    Article  CAS  PubMed  Google Scholar 

  4. Uemura N. The magnitude of association between Helicobacter pylori infection and the development of gastric cancer. Scand J Gastroenterol. 2002;37(8):869–70.

    Article  CAS  PubMed  Google Scholar 

  5. Takashima T, Adachi K, Kawamura A, Yuki M, Fujishiro H, Rumi MA, et al. Cardiovascular risk factors in subjects with Helicobacter pylori infection. Helicobacter. 2002;7(2):86–90.

    Article  PubMed  Google Scholar 

  6. Zycinska K, Wardyn KA, Zycinski Z, Smolarczyk R. Correlation between Helicobacter pylori infection and pulmonary Wegener’s granulomacytosis activity. J Physiol Pharmacol. 2008;59(Suppl 6):845–51.

    PubMed  Google Scholar 

  7. Salama NR, Hartung ML, Muller A. Life in the human stomach: persistence strategies of the bacterial pathogen Helicobacter pylori. Nat Rev Microbiol. 2013;11(6):385–99. doi:10.1038/nrmicro3016.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  8. Li HB, Zhang JY, He YF, Chen L, Li B, Liu KY, et al. Systemic immunization with an epitope-based vaccine elicits a Th1-biased response and provides protection against Helicobacter pylori in mice. Vaccine. 2012;31(1):120–6. doi:10.1016/j.vaccine.2012.10.091.

    Article  PubMed  Google Scholar 

  9. Lycke N. Recent progress in mucosal vaccine development: potential and limitations. Nat Rev Immunol. 2012;12(8):592–605. doi:10.1038/nri3251.

    Article  CAS  PubMed  Google Scholar 

  10. McCluskie MJ, Davis HL. CpG DNA as mucosal adjuvant. Vaccine. 1999;18(3–4):231–7.

    Article  CAS  PubMed  Google Scholar 

  11. Ki MR, Hong IH, Park JK, Hong KS, Hwang OK, Han JY, et al. Potent neutralization of vacuolating cytotoxin (VacA) of Helicobacter pylori by immunoglobulins against the soluble recombinant VacA. Anticancer Res. 2009;29(6):2393–402.

    CAS  PubMed  Google Scholar 

  12. Banerjee S, Medina-Fatimi A, Nichols R, Tendler D, Michetti M, Simon J, et al. Safety and efficacy of low dose Escherichia coli enterotoxin adjuvant for urease based oral immunisation against Helicobacter pylori in healthy volunteers. Gut. 2002;51(5):634–40.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  13. Pizza M, Giuliani MM, Fontana MR, Monaci E, Douce G, Dougan G, et al. Mucosal vaccines: non toxic derivatives of LT and CT as mucosal adjuvants. Vaccine. 2001;19(17–19):2534–41.

    Article  CAS  PubMed  Google Scholar 

  14. Marchetti M, Rossi M, Giannelli V, Giuliani MM, Pizza M, Censini S, et al. Protection against Helicobacter pylori infection in mice by intragastric vaccination with H. pylori antigens is achieved using a non-toxic mutant of E. coli heat-labile enterotoxin (LT) as adjuvant. Vaccine. 1998;16(1):33–7.

    Article  CAS  PubMed  Google Scholar 

  15. Zhou WY, Shi Y, Wu C, Zhang WJ, Mao XH, Guo G, et al. Therapeutic efficacy of a multi-epitope vaccine against Helicobacter pylori infection in BALB/c mice model. Vaccine. 2009;27(36):5013–9. doi:10.1016/j.vaccine.2009.05.009.

    Article  CAS  PubMed  Google Scholar 

  16. Takahashi I, Marinaro M, Kiyono H, Jackson RJ, Nakagawa I, Fujihashi K, et al. Mechanisms for mucosal immunogenicity and adjuvancy of Escherichia coli labile enterotoxin. J Infect Dis. 1996;173(3):627–35.

    Article  CAS  PubMed  Google Scholar 

  17. Lee CK, Weltzin R, Thomas WD Jr, Kleanthous H, Ermak TH, Soman G, et al. Oral immunization with recombinant Helicobacter pylori urease induces secretory IgA antibodies and protects mice from challenge with Helicobacter felis. J Infect Dis. 1995;172(1):161–72.

    Article  CAS  PubMed  Google Scholar 

  18. Roussel Y, Wilks M, Harris A, Mein C, Tabaqchali S. Evaluation of DNA extraction methods from mouse stomachs for the quantification of H. pylori by real-time PCR. J Microbiol Methods. 2005;62(1):71–81. doi:10.1016/j.mimet.2005.01.011.

    Article  CAS  PubMed  Google Scholar 

  19. Chen Q, Jackson H, Parente P, Luke T, Rizkalla M, Tai TY, et al. Immunodominant CD4+ responses identified in a patient vaccinated with full-length NY-ESO-1 formulated with ISCOMATRIX adjuvant. Proc Natl Acad Sci USA. 2004;101(25):9363–8. doi:10.1073/pnas.0403271101.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  20. Wu C, Zanker D, Valkenburg S, Tan B, Kedzierska K, Zou QM, et al. Systematic identification of immunodominant CD8+ T-cell responses to influenza A virus in HLA-A2 individuals. Proc Natl Acad Sci USA. 2011;108(22):9178–83. doi:10.1073/pnas.1105624108.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  21. Brown LJ, Rosatte RC, Fehlner-Gardiner C, Ellison JA, Jackson FR, Bachmann P, et al. Oral vaccination and protection of striped skunks (Mephitis mephitis) against rabies using ONRAB(R). Vaccine. 2014;32(29):3675–9. doi:10.1016/j.vaccine.2014.04.029.

    Article  CAS  PubMed  Google Scholar 

  22. Johansson EL, Bergquist C, Edebo A, Johansson C, Svennerholm AM. Comparison of different routes of vaccination for eliciting antibody responses in the human stomach. Vaccine. 2004;22(8):984–90. doi:10.1016/j.vaccine.2003.09.002.

    Article  CAS  PubMed  Google Scholar 

  23. Bergquist C, Johansson EL, Lagergard T, Holmgren J, Rudin A. Intranasal vaccination of humans with recombinant cholera toxin B subunit induces systemic and local antibody responses in the upper respiratory tract and the vagina. Infect Immun. 1997;65(7):2676–84.

    CAS  PubMed Central  PubMed  Google Scholar 

  24. Ogra PL, Faden H, Welliver RC. Vaccination strategies for mucosal immune responses. Clin Microbiol Rev. 2001;14(2):430–45. doi:10.1128/CMR.14.2.430-445.2001.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  25. Mestecky J. The common mucosal immune system and current strategies for induction of immune responses in external secretions. J Clin Immunol. 1987;7(4):265–76.

    Article  CAS  PubMed  Google Scholar 

  26. Holmgren J, Czerkinsky C. Mucosal immunity and vaccines. Nat Med. 2005;11(4 Suppl):S45–53. doi:10.1038/nm1213.

    Article  CAS  PubMed  Google Scholar 

  27. Londono-Arcila P, Freeman D, Kleanthous H, O’Dowd AM, Lewis S, Turner AK, et al. Attenuated Salmonella enterica serovar Typhi expressing urease effectively immunizes mice against Helicobacter pylori challenge as part of a heterologous mucosal priming-parenteral boosting vaccination regimen. Infect Immun. 2002;70(9):5096–106.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  28. Jiang W, Baker HJ, Smith BF. Mucosal immunization with helicobacter, CpG DNA, and cholera toxin is protective. Infect Immun. 2003;71(1):40–6.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  29. Shi T, Liu WZ, Gao F, Shi GY, Xiao SD. Intranasal CpG-oligodeoxynucleotide is a potent adjuvant of vaccine against Helicobacter pylori, and T helper 1 type response and interferon-gamma correlate with the protection. Helicobacter. 2005;10(1):71–9. doi:10.1111/j.1523-5378.2005.00293.x.

    Article  CAS  PubMed  Google Scholar 

  30. Begue RE, Sadowska-Krowicka H. Protective efficacy of recombinant urease B and aluminum hydroxide against Helicobacter pylori infection in a mouse model. FEMS Immunol Med Microbiol. 2010;60(2):142–6. doi:10.1111/j.1574-695X.2010.00726.x.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  31. Weltzin R, Guy B, Thomas WD Jr, Giannasca PJ, Monath TP. Parenteral adjuvant activities of Escherichia coli heat-labile toxin and its B subunit for immunization of mice against gastric Helicobacter pylori infection. Infect Immun. 2000;68(5):2775–82.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  32. Shiomi S, Toriie A, Imamura S, Konishi H, Mitsufuji S, Iwakura Y, et al. IL-17 is involved in Helicobacter pylori-induced gastric inflammatory responses in a mouse model. Helicobacter. 2008;13(6):518–24. doi:10.1111/j.1523-5378.2008.00629.x.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  33. Skene CD, Doidge C, Sutton P. Evaluation of ISCOMATRIX and ISCOM vaccines for immunisation against Helicobacter pylori. Vaccine. 2008;26(31):3880–4. doi:10.1016/j.vaccine.2008.05.004.

    Article  CAS  PubMed  Google Scholar 

  34. Hitzler I, Oertli M, Becher B, Agger EM, Muller A. Dendritic cells prevent rather than promote immunity conferred by a helicobacter vaccine using a mycobacterial adjuvant. Gastroenterology. 2011;141(1):186–96. doi:10.1053/j.gastro.2011.04.009.

    Article  CAS  PubMed  Google Scholar 

  35. Czerkinsky C, Holmgren J. Topical immunization strategies. Mucosal Immunol. 2010;3(6):545–55. doi:10.1038/mi.2010.55.

    Article  CAS  PubMed  Google Scholar 

  36. Hilton C, Wiedmann T, St Martin M, Humphrey B, Schleiffarth R, Rimell F. Differential deposition of aerosols in the maxillary sinus of human cadavers by particle size. Am J Rhinol. 2008;22(4):395–8. doi:10.2500/ajr.2008.22.3192.

    Article  PubMed  Google Scholar 

  37. Alving CR. Design and selection of vaccine adjuvants: animal models and human trials. Vaccine. 2002;20(Suppl 3):S56–64.

    Article  CAS  PubMed  Google Scholar 

  38. Chuang SC, Yang CD. Sustained release of recombinant surface antigen 2 (rSAG2) from poly(lactide-co-glycolide) microparticles extends protective cell-mediated immunity against Toxoplasma gondii in mice. Parasitology. 2014;. doi:10.1017/S0031182014000997.

    PubMed  Google Scholar 

  39. Lumsden JM, Nurmukhambetova S, Klein JH, Sattabongkot J, Bennett JW, Bertholet S, et al. Evaluation of immune responses to a Plasmodium vivax CSP-based recombinant protein vaccine candidate in combination with second-generation adjuvants in mice. Vaccine. 2012;30(22):3311–9. doi:10.1016/j.vaccine.2012.03.004.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This work was supported by the National Key Technology R&D Program of China (2014BAI15B00/2014BAI15B01), the National Twelfth Five Year Plan ‘‘863’’ major projects of China (No. 2012AA02A405-3), the National Natural Science Foundation of China (No. 81373134) and the Chongqing Natural Science Foundation (cstc2013jcyjA1037)

Conflict of interest

The authors declare no conflict of interests.

Author information

Authors and Affiliations

  1. Department of Microbiology and Biochemical Pharmacy, National Engineering Research Center of Immunological Products, College of Pharmacy, Third Military Medical University, Chongqing, 400038, People’s Republic of China

    Haibo Li, Jinyong Zhang, Yafei He, Bin Li, Li Chen, Quanming Zou & Chao Wu

  2. Department of Medicinal Chemistry, College of Pharmacy, Third Military Medical University, Chongqing, 400038, People’s Republic of China

    Haibo Li

  3. Department of Clinical Laboratory, Xinqiao Hospital, Third Military Medical University, Chongqing, 400037, People’s Republic of China

    Weiwei Huang

Authors
  1. Haibo Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jinyong Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yafei He
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Bin Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Li Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Weiwei Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Quanming Zou
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Chao Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Quanming Zou or Chao Wu.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Li, H., Zhang, J., He, Y. et al. Intranasal immunization with an epitope-based vaccine results in earlier protection, but not better protective efficacy, against Helicobacter pylori compared to subcutaneous immunization. Immunol Res 62, 368–376 (2015). https://doi.org/10.1007/s12026-015-8666-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12026-015-8666-9

Keywords

Search

Navigation